Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors

Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of
directors

SEATTLE, Oct. 5 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:
ONY) today announced the appointment of Douglas E. Williams, Ph.D., Chief
Executive Officer of ZymoGenetics, Inc. (Nasdaq: ZGEN), to its board of
directors.
"We are pleased to welcome Doug to our board of directors and look forward to
the contributions he will make to Oncothyreon. His extensive experience in
drug development, research and operations will be invaluable," said Robert L.
Kirkman, M.D., President and Chief Executive Officer of Oncothyreon.
Dr. Williams joined ZymoGenetics in 2004 and has served as a director and
Chief Executive Officer since January 2009. He has held senior level positions
at a number of prominent biotechnology companies, including Seattle Genetics,
Inc., Immunex Corporation, and Amgen, Inc. As Executive Vice President and
Chief Technology Officer at Immunex, Dr. Williams played a significant role in
the discovery and early development of Enbrel, the first biologic approved for
the treatment of rheumatoid arthritis. Dr. Williams currently serves as a
director of Array BioPharma Inc. and Aerovance, Inc. Dr. Williams received a
B.S. (magna cum laude) in Biological Sciences from the University of
Massachusetts, Lowell and a Ph.D. in Physiology from the State University of
New York at Buffalo, Roswell Park Cancer Institute Division.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of
innovative therapeutic products for the treatment of cancer. Oncothyreon's
goal is to develop and commercialize novel synthetic vaccines and targeted
small molecules that have the potential to improve the lives and outcomes of
cancer patients. For more information, visit www.oncothyreon.com.

SOURCE Oncothyreon Inc.

Investor and Media Relations Contact: Julie Rathbun, Rathbun Communications,
(206) 769-9219, ir@oncothyreon.com